I think we need to distinguish between trade policy and contract negotiations in this context, but I would say this. We have been having discussions on trying to remove barriers to the movement of inputs to vaccines and vaccine production, and we have been discussing ways that these things can move much more easily within the global context.
I would also say that the director-general's third way, where she's engaging with industry and with stakeholders, is meant to facilitate these types of discussions to see what can be done to facilitate the movement of vaccines, but also to facilitate the production of vaccines. The individual contract negotiations themselves fall outside of the ambit of the WTO, so in fact, what the DG is engaging in is almost, in certain respects, an issue of moral suasion to work with industry.